New report urges more clinical trial diversity, recommends incentives

A new report commissioned by Congress makes significant recommendations for improving clinical trial diversity, including offering financial incentives that have typically been off the table for ethical reasons. The 403-page report addresses a range of stakeholders but specifically urges the US Food and Drug Administration (FDA) to hold sponsors accountable for enrolling more diverse participants in trials.